The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study
Edward J D Webb,Daniel Howdon,Rebecca Bestwick,Natalie King,Jonathan A T Sandoe,Joanne Euden,Detelina Grozeva,Robert West,Philip Howard,Neil Powell,Mahableshwar Albur,Stuart Bond,Lucy Brookes-Howell,Paul Dark,Thomas Hellyer,Martin Llewelyn,Iain J McCullagh,Margaret Ogden,Philip Pallmann,Helena Parsons,David Partridge,Dominick Shaw,Tamas Szakmany,Stacy Todd,Emma Thomas-Jones,Enitan D Carrol,Bethany Shinkins,PEACH Study Group,Jonathan Sandoe,Enitan Carrol,Josie Henley,Wakunyambo Maboshe,Marcin Bargiel,Judith Evans,Edward Webb,Colin Richman,Sarah Gerver,Russell Hope,Susan Hopkins,Margaret Heginbothom,Claire Berry,Georgina Davis,Vikki Wilkinson,Eleanor Taylor-Barr,Mary Brodsky,Jo Brown,Jenni Burns,Sharon Glynn,Alvyda Gureviciute,Megan Howard,Jennifer Kirkpatrick,Hannah Murphy,Emma Richardson,Deborah Scanlon,Claire Small,Graham Sweeney,Lisa Williams,Evelyn Baker,Yusuf Cheema,Jill Dunhill,Charlotte Killick,Charlie King,Simran Kooner,Swyn Lewis,Maxine Nash,Owen Richardson,Jemma Tuffney,Clare Westacott,Sarah Williams,Kay Cawthron,Yuen Kiu Tai,Thomas Newman,Megan Plowright,Helen Shulver,Anna Sivakova,Freddie Ayliffe,Emma Darke,Eve Fletcher,Fiona Hammonds,Gladys Marquez,Leanne Welch,Jade Lee-Milner,Joseph Spencer,Rodrigo Brandao,Joshua Hrycaiczuk,Jack Stanley,Elizabeth Cross,Daniel Hansen,Ethan Redmore,Abigail Whyte,Tom Hellyer,Iain McCullagh,Benjamin Brown,Michele Calabrese,Cameron Cole,Jessica DeSousa,Leigh Dunn,Stephanie Grieveson,Arti Gulati,Elizabeth Issac,Ruaridh Mackay,Fatima Simoes,Elena Apatri,Bethan Charles,Helen Christensen,Alice Harvey,Diane Lomas,Melanie Taylor,Vicky Thomas,Danielle Walker,Lucy Howard,Amelia Joseph,Saheer Sultan,Chikezie Knox-Macaulay,Graham Prestwich,Ryan Hamilton
DOI: https://doi.org/10.1093/jac/dkae167
2024-08-01
Abstract:Background: Many hospitals introduced procalcitonin (PCT) testing to help diagnose bacterial coinfection in individuals with COVID-19, and guide antibiotic decision-making during the COVID-19 pandemic in the UK. Objectives: Evaluating cost-effectiveness of using PCT to guide antibiotic decisions in individuals hospitalized with COVID-19, as part of a wider research programme. Methods: Retrospective individual-level data on patients hospitalized with COVID-19 were collected from 11 NHS acute hospital Trusts and Health Boards from England and Wales, which varied in their use of baseline PCT testing during the first COVID-19 pandemic wave. A matched analysis (part of a wider analysis reported elsewhere) created groups of patients whose PCT was/was not tested at baseline. A model was created with combined decision tree/Markov phases, parameterized with quality-of-life/unit cost estimates from the literature, and used to estimate costs and quality-adjusted life years (QALYs). Cost-effectiveness was judged at a £20 000/QALY threshold. Uncertainty was characterized using bootstrapping. Results: People who had baseline PCT testing had shorter general ward/ICU stays and spent less time on antibiotics, though with overlap between the groups' 95% CIs. Those with baseline PCT testing accrued more QALYs (8.76 versus 8.62) and lower costs (£9830 versus £10 700). The point estimate was baseline PCT testing being dominant over no baseline testing, though with uncertainty: the probability of cost-effectiveness was 0.579 with a 1 year horizon and 0.872 with a lifetime horizon. Conclusions: Using PCT to guide antibiotic therapy in individuals hospitalized with COVID-19 is more likely to be cost-effective than not, albeit with uncertainty.